OptimizeRx Corp.

Total Valuation

OptimizeRx Corp. carries a market capitalization of 176.49M, placing it among publicly traded companies globally. Its enterprise value stands at 103.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

OptimizeRx Corp. currently has 18.83M shares outstanding.

Valuation Ratios

OptimizeRx Corp. trades at a trailing price-to-earnings ratio of 23.24. The price-to-sales ratio is 1.08, and the price-to-book ratio stands at 0.82.

Enterprise Valuation

On an enterprise value basis, OptimizeRx Corp. trades at an EV/EBITDA multiple of 6.62 and an EV/FCF ratio of 4.75. The EV/Sales ratio of 1.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.13 provides insight into valuation relative to core operating earnings.

Financial Position

OptimizeRx Corp. maintains a current ratio of 5.58, meaning it holds 5.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.86, indicating elevated leverage, while an interest coverage ratio of 3.33 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

OptimizeRx Corp. posts a return on equity of 3.68 and a return on invested capital of 5.14.

Taxes

Over the trailing twelve months, OptimizeRx Corp. has paid 2.18M in income taxes, reflecting an effective tax rate of 32.14.

Stock Price Statistics

OptimizeRx Corp.'s stock has declined approximately -52.77218% over the past 52 weeks. The 50-day moving average sits at 8.01, while the 200-day moving average is 7.46.

Income Statement

Over the trailing twelve months, OptimizeRx Corp. generated 98.65M in revenue and converted that into 4.60M in net income, yielding earnings per share of 0.24. EBITDA reached 15.58M, while operating income came in at 11.30M.

Balance Sheet

OptimizeRx Corp. holds 24.10M in cash and equivalents against 19.48M in total debt, resulting in a net debt position of -5.09M. Total book value stands at 131.08M, with working capital of 44.44M providing operational flexibility.

Cash Flow

OptimizeRx Corp. produced 18.43M in operating cash flow over the past twelve months. After subtracting -77,000.00 in capital expenditures, free cash flow totaled 18.36M - equivalent to 0.98 per share.

Margins

OptimizeRx Corp. operates with a gross margin of 73.22, reflecting its pricing power and cost economics. The operating margin of 11.45 and net profit margin of 4.66 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

OptimizeRx Corp.'s most recent stock split took place on May 14, 2018 with a 3:1 split ratio.

Scores

OptimizeRx Corp. posts an Altman Z-Score of 3.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.